Opinion of Belgian neurologists on antiepileptic drug treatment in 2006: Belgian study on epilepsy treatment (BESET-2)

Acta Neurologica Scandinavica

Volumn 120, Issue 6, 2009, Pages 402-410

  Legros, B ^a   Boon, P ^b   De Jonghe, P ^c   Sadzot, B ^d   Van Rijckevorsel, K ^e   Schmedding, E ^f  

^a ERASME HOSPITAL   (Belgium)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

^c ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^d CHU SART TILMAN   (Belgium)

^e Department of Neurology   (Belgium)

^f UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

Author keywords

Antiepileptic drugs; Consensus; Epilepsy; Expert; Survey; Treatment

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; ETIRACETAM; LAMOTRIGINE; OXCARBAZEPINE; PHENYTOIN; TOPIRAMATE; VALPROIC ACID;

ABSENCE; ANTICONVULSANT THERAPY; ARTICLE; BELGIUM; CONSENSUS DEVELOPMENT; CONTROLLED STUDY; DRUG INDICATION; DRUG PREFERENCE; DRUG UTILIZATION; EPILEPSY; FOCAL EPILEPSY; GENERALIZED EPILEPSY; HEALTH SURVEY; MONOTHERAPY; PHYSICIAN; PUBLIC OPINION; STRUCTURED INTERVIEW; STRUCTURED QUESTIONNAIRE; TONIC CLONIC SEIZURE;

ADULT; ANTICONVULSANTS; BELGIUM; CONSENSUS; DATA COLLECTION; EPILEPSY; FEMALE; HUMANS; MALE; PHYSICIAN'S PRACTICE PATTERNS; PREGNANCY; QUESTIONNAIRES;

EID: 72849144336     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2009.01182.x     Document Type: Article

References (23)

1. French JA, Kanner AM, Bautista J et al. Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2004 62 : 1261 73.
2. French JA, Kanner AM, Bautista J et al. Efficacy and tolerability of the new antiepileptic drugs I: treatment of new onset epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2004 62 : 1252 60.
3. French JA, Kanner AM, Bautista J et al. Efficacy and tolerability of the new antiepileptic drugs, II: Treatment of refractory epilepsy: report of the TTA and QSS Subcommittees of the American Academy of Neurology and the American Epilepsy Society. Epilepsia 2004 45 : 410 23.
4. French JA, Kanner AM, Bautista J et al. Efficacy and tolerability of the new antiepileptic drugs, I: Treatment of new-onset epilepsy: report of the TTA and QSS Subcommittees of the American Academy of Neurology and the American Epilepsy Society. Epilepsia 2004 45 : 401 9.
5. National Institute for Clinical Excellence. The diagnosis and management of the epilepsies in adults and children in primary and secondary care. Clinical Guideline 20 October 2004. Available at: www nice org ukCG020NICEguideline, 2004.
6. Glauser T, Ben-Menachem E, Bourgeois B et al. ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 2006 47 : 1094 120.
7. Legros B, Boon P, Dejonghe P, Sadzot B, Van Rijckevorsel K, Schmedding E. Opinion of Belgian Neurologists on antiepileptic drugs: Belgian Study on Epilepsy Treatment (BESET). Acta Neurol Scand 2007 115 : 97 103.
8. Boon P, Dejonghe P, Legros B, Sadzot B, Van Rijckevorsel K, Schmedding E. Impact of reimbursement restrictions on the choice of antiepileptic drugs: Belgian Study on Epilepsy Treatment (BESET). Seizure 2008 17 : 350 7.
9. Karceski S, Morrell M, Carpenter D. The expert consensus guideline series: treatment of epilepsy. Epilepsy Behav 2001 2 : A1 50.
10. Karceski S, Morrell MJ, Carpenter D. Treatment of epilepsy in adults: expert opinion, 2005. Epilepsy Behav 2005 7 (Suppl. 1) : S1 64.
11. Reinikainen KJ, Keränen T, Halonen T, Komulainen H, Riekkinen PJ. Comparison of oxcarbazepine and carbamazepine: a double-blind study. Epilepsy Res 1987 1 : 284 9.
12. Dam M, Ekberg R, Løyning Y, Waltimo O, Jakobsen K. A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy. Epilepsy Res 1989 3 : 70 6.
13. Morrow J, Russell A, Guthrie E et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry 2006 77 : 193 8.
14. Holmes LB, Baldwin EJ, Smith CR et al. Increased frequency of isolated cleft palate in infants exposed to lamotrigine during pregnancy. Neurology 2008 70 : 2152 8.
15. Mulleners WM, Chronicle EP. Anticonvulsants in migraine prophylaxis: a Cochrane review. Cephalalgia 2008 28 : 585 97 (Review).
16. PACK A. Bone health in people with epilepsy: is it impaired and what are the risk factors? Seizure 2008 17 : 181 6.
17. Ryvlin P, Montavont A, Nighoghossian N. Optimizing therapy of seizures in stroke patients. Neurology 2006 67 : S3 9.
18. Biton V, Montouris GD, Ritter F et al. A randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures. Topiramate YTC Study Group. Neurology 1999 52 : 1330 7.
19. Verdru P, Wajgt A, Schiemann Delgado J et al. Efficacy and safety of levetiracetam 3000 mgd as adjunctive treatment in adolescents and adults suffering from idiopathic generalized epilepsy with myoclonic seizures. Epilepsia 2005 46 (Suppl. 6) : 56 7.
20. Noachtar S, Andermann E, Meyvisch P et al. Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures. Neurology 2008 70 : 607 16.
21. Privitera MD, Brodie MJ, Mattson RH et al. Topiramate, carbamazepine and valproate monotherapy: double-blind comparison in newly diagnosed epilepsy. Acta Neurol Scand 2003 107 : 165 75.
22. Gilliam FG, Veloso F, Bomhof MA et al. A dose-comparison trial of topiramate as monotherapy in recently diagnosed partial epilepsy. Neurology 2003 60 : 196 202.
23. Brodie MJ, Perucca E, Ryvlin P, Ben-Menachem E, Meencke HJ, Levetiracetam Monotherapy Study Group. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology 2007 68 : 402 8.